Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drop-the-losers design: normal case.

Allan R Sampson1, Michael W Sill

  • 1Department of Statistics, University of Pittsburgh, 2701 Cathedral of Learning, Pittsburgh, PA 15260, USA. msill@gogstats.org

Biometrical Journal. Biometrische Zeitschrift
|August 2, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.

Gynecologic oncology·2025
Same author

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.

Nature medicine·2025
Same author

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

The New England journal of medicine·2023
Same author

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.

Gynecologic oncology·2023
Same author

Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).

Molecular cancer therapeutics·2020
Same journal

When to Adjust for Multiple Testing: A Unifying Guiding Principle.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Ensuring Quality in Preclinical Research: The Importance of Being Human.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Addressing Cluster-Level Treatment Effect Heterogeneity in Sample Size Determination for Hierarchical 2 × 2 Factorial Designs.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

A Multiple Imputation Approach to Distinguish Curative From Life-Prolonging Effects in the Presence of Missing Covariates.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Tests for Categorical Data Beyond Pearson: A Distance Covariance and Energy Distance Approach.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Nonparametric Estimation of the Patient-Weighted While-Alive Estimand.

Biometrical journal. Biometrische Zeitschrift·2026
See all related articles

Drop-the-losers designs offer a two-stage clinical trial approach, selecting the best treatment early. This method corrects statistical inaccuracies, ensuring reliable confidence intervals for biopharmaceutical research.

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmaceutical Research

Background:

  • Drop-the-losers designs involve sequential stages with data-based treatment selection.
  • Traditional inference methods can inflate significance levels and reduce confidence interval accuracy.

Purpose of the Study:

  • To provide corrected statistical methods for drop-the-losers designs.
  • To ensure accurate confidence intervals and significance levels in two-stage trials.

Main Methods:

  • Development of statistical methods for normally distributed data in two-stage trials.
  • Correction of traditional inference techniques to account for data-based treatment selection.

Main Results:

  • The proposed methods yield confidence intervals with accurate confidence levels.

Related Experiment Videos

  • Corrected tests maintain the advertised levels of significance.

    • Conclusions:

    • Drop-the-losers designs can integrate Phase II and III trials under one protocol.
    • Accurate statistical inference is crucial for biopharmaceutical clinical trials using these designs.